Evaluation of aqueous humor concentrations of Istalol® and Betimol® following a single ocular instillation in rabbit eyes

Journal of Ocular Pharmacology and Therapeutics

Volumn 24, Issue 5, 2008, Pages 507-512

  Baklayan, George A ^a,b   Collins, Erin C ^a   Thetford, Tim ^a   Soriano, Arnel ^a   Song, Clara K ^a   Han, John ^a  

^a ISTA Pharmaceuticals Inc   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TIMOLOL; TIMOLOL MALEATE;

ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; RABBIT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ABSORPTION; ADMINISTRATION, TOPICAL; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; AQUEOUS HUMOR; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG COMBINATIONS; FEMALE; OPHTHALMIC SOLUTIONS; PERMEABILITY; RABBITS; SORBIC ACID; THERAPEUTIC EQUIVALENCY; TIMOLOL; TISSUE DISTRIBUTION;

EID: 52449117762     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2007.0131     Document Type: Article

References (15)

1. Shields, M.R. Adrenergic inhibitors. In: Textbook of Glaucoma, 3rd ed. Williams & Wilkins, 1992:480-499.
2. Bobik, A., Jennings, G.L., Ashley, P., et al. Timolol pharmacokinetics and effects on heart rate and blood pressure after acute and chronic administration. Eur. J. Clin. Pharmacol. 16:243-249, 1979.
3. Akafo, S.K., Thompson, J.R., and Rosenthal, A.R. A cross-over trial comparing once-daily levobunolol with once- and twice-daily timolol. Eur. J. Ophthalmol. 5:172-176, 1995.
4. Patel, S.C., and Spaeth, G.L. Compliance in patients prescribed eyedrops for glaucoma. Ophthal. Surg. 26:233-236, 1995.
5. Ikeda, H., Sato, M., Tsukamoto, H., et al. Evaluation and multivariate statistical analysis of factors influencing patient adherence to ophthalmic solutions. Yakugaku Zasshi. 121:799-806, 2001.
6. Chien, D.S., Bundgaard, H, and Lee, V.H.L. Influence of corneal epithelial integrity on the penetration of timolol drugs. J. Ocul. Pharmacol. Ther. 4:137-146. 1988.
7. Friedrich S.W., Saville, B.A., Cheng, Y.L., et al. Pharmacokinetic differences between ocular inserts and eyedrops. J. Ocul. Pharmacol. Ther. 12:5-18, 1996.
8. Shedden, A.H. Timolol maleate in gel-forming solution. A novel formulation of timolol maleate. Chibret. Int. J. Ophthalmol. 10:32-36, 1994.
9. Shedden, A, Laurence, J., and Tipping, R., for the Timoptic-XE 0.5% Study Group. Efficacy and tolerability of timolol maleate ophthalmic gel-forming solution versus timolol ophthalmic solution in adults with open-angle glaucoma or ocular hypertension: A six-month, double-masked, multicenter study. Clin. Ther. 23:440-450, 2001.
10. El-Kamel, A.H. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. Int. J. Pharm. 241:47-55, 2002.
11. Rhee, D.J. TIMOPTIC-XE®. In: Physicians' Desk Reference, 32nd ed. Montvale, NJ: Thomson PDR, 2004:277-281.
12. Higashiyama, M., Inada, K., Ohtori, A., et al. Improvement of the ocular availability of timolol by sorbic acid. Int. J. Pharmaceut. 272:91-98, 2004.
13. Mundorf, T.K., Ogawa, T., Inui, N., et al. Timolol-LA: A double-masked, active-controlled, randomized, cross-over, comfort, ocular safety, and systemic bioavailablity study in healthy volunteers. Curr. Med. Res. Opin. 21:369-373, 2005.
14. Mundorf, T.K., Ogawa, T, Naka, H., et al., for the U.S. Istalol Study Group. A 12-month, multicenter, randomized, double-masked, parallel-group comparison of timolol-LA once-daily and timolol maleate ophthalmic solution twice-daily in the treatment of adults with glaucoma or ocular hypertension. Clin. Ther. 26:541-551, 2004.
15. Stewart, W.C., Cate, E.A., and Stewart, J.A. Systemic beta-blockade with once daily Betimol or Timoptic-XE. J. Ocul. Pharmacol. Ther. 15:225-231, 1999.